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Influence of Continuous Infusion
of Low-Dose Human Atrial Natriuretic Peptide
on Renal Function During Cardiac Surgery
A Randomized Controlled Study
Akira Sezai, MD, PHD,* Mitsumasa Hata, MD, PHD,* Tetsuya Niino, MD, PHD,*
Isamu Yoshitake, MD, PHD,* Satoshi Unosawa, MD, PHD,* Shinji Wakui, MD, PHD,*
Shunji Osaka, MD, PHD,* Tadateru Takayama, MD, PHD,† Yuji Kasamaki, MD, PHD,†
Atsushi Hirayama, MD, PHD,† Kazutomo Minami, MD, PHD*
Tokyo, Japan
Objectives The purpose of this study was to determine the effect of human atrial natriuretic peptide (hANP) in patients who
underwent coronary artery bypass grafting (CABG) on renal function.
Background Acute renal failure after cardiac surgery is associated with high morbidity and mortality.
Methods A total of 504 patients who underwent CABG were divided into 2 groups: 1 group received hANP at 0.02 g/kg/
min from the start of cardiopulmonary bypass (hANP group), and 1 group did not receive hANP (placebo group).
Various parameters were measured before and after surgery.
Results There was no difference in mortality between the 2 groups, but post-operative complications were less frequent
in the hANP group (p  0.0208). In the hANP group, serum creatinine (Cr) was significantly lower and urinary Cr
and Cr clearance were significantly higher from post-operative day 1 to week 1. The maximum post-operative Cr
level and percent increase of Cr were significantly lower in the hANP group (p  0.0001). Patients with Cr ex-
ceeding 2.0 mg/dl included 1 in the hANP group and 8 in the placebo group, showing a significant difference
(p  0.0374). Four patients in the placebo group and none in the hANP group required hemodialysis, but the
difference was not statistically significant.
Conclusions Continuous infusion of low-dose hANP from the start of cardiopulmonary bypass effectively maintained post-
operative renal function. Infusion of hANP prevents early post-operative acute renal failure and helps to achieve
safer cardiac surgery. (Clinical Trial registration number: UMIN000001440) (J Am Coll Cardiol 2009;54:
1058–64) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.047r
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Ccute renal failure occurs after cardiac surgery in 2.4% to
6% of patients who have normal renal function pre-
peratively, and the prognosis of such patients is relatively
oor, with a mortality rate of 1.3% to 30% (1–3). The
ortality rate rises to 33% to 63.7% in patients requiring
emodialysis (2,4,5). Deterioration of renal function after
ardiac surgery is considered to be attributable to cardiopul-
onary bypass (CPB) in many cases, and it has been
rom the Departments of *Cardiovascular Surgery and †Cardiology, Nihon Univer-
ity School of Medicine, Tokyo, Japan. This study was supported by a grant for the
0th Anniversary of the Alumni Association of Nihon University School of Medicine
nd for the 50th Anniversary of the Foundation of Nihon University School of
edicine. The sponsors of the study had no role in study design, data collection, data
nalysis, data interpretation, or writing of the report.t
Manuscript received January 8, 2009; revised manuscript received April 29, 2009,
ccepted May 25, 2009.eported that off-pump coronary artery bypass (OPCAB) is
ess frequently associated with complications such as acute
enal failure and stroke (6,7). On the other hand, it has also
een reported that OPCAB is associated with a lower graft
atency rate and post-operative angina, and that there is no
ifference in post-operative renal function (8–11). The
nnual report of the Japanese Association for Coronary Artery
urgery stated that fewer bypasses were performed with
PCAB and that the mortality was a high 3.7% among
atients who were switched from OPCAB to on-pump coro-
ary artery bypass grafting (CABG) during surgery (12).
ecent improvements of surgical techniques and progress in
yocardial protection and post-operative management have
ed to better results of surgery. The most important factor in
ABG is the quality of the grafts, and we generally performhis surgery by using CPB at our institution.
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September 15, 2009:1058–64 Ef fects of hANP in Cardiac SurgeryHuman atrial natriuretic peptide (hANP) is a hormone
hat is secreted in response to stretching of the atrial wall.
t has a vasodilatory effect and a potent natriuretic effect,
t suppresses the renin-angiotensin-aldosterone system
RAAS), and it causes coronary artery dilation, and has
hus been used clinically as a new drug for the treatment
f cardiac failure and acute myocardial infarction (13–15).
uring cardiac surgery, an abnormal increase of RAAS
ormones and catecholamines may result from the influence
f CPB, and this can trigger a decrease of urine output and
etention of water in the third space. We considered that
ANP could be effective against this pathological situation,
nd we previously reported that continuous infusion
f low-dose hANP from the start of CPB was effective
ompensation for the defects of CPB and suppressed left
entricular remodeling by blocking the RAAS and pro-
oting natriuresis (16 –18). All previous studies of hANP
nfusion have been small in scale, but we conducted a
andomized, controlled, multicenter (7 institutions of
ihon University Group) study in 500 patients to assess
he effect of hANP infusion during CPB on post-operative
enal function.
ethods
atients. A total of 504 patients without renal impairment
evaluated by a serum creatinine [Cr] 1.3 mg/dl and a
reatinine clearance [Ccr] 80 ml/min) underwent CABG.
hose who had renal impairment pre-operatively and re-
uired hemodialysis due to pre-operative shock were ex-
luded. The patients were randomly allocated to 2 groups by
rawing lots: 1 group received infusion of hANP (Suntory
nc., Osaka, Japan, and Daiichi Sankyo Co., Ltd., Tokyo,
apan) in a blinded manner (hANP group) and 1 group
eceived physiological saline in the same manner (placebo
roup). This study was approved by the ethical committee of
ihon University School of Medicine, and an explanation
as given to each patient before obtaining consent. Infusion
f hANP or saline was started at 0.02 g/kg/min from the
ommencement of CPB. It was reduced to 0.01 g/kg/min
fter the start of oral medication, and then stopped after
nother 12 h. In the placebo group, the saline infusion was
andled in the same manner. In all patients, CABG was
erformed under CPB (Jostra HL-20, Jostra AG, Hirrlin-
en, Germany) with nonpulsatile perfusion at a reduced
emperature (rectal temperature: 34°C). In all cases, the left
nternal thoracic artery was used for anastomosis to the left
nterior descending artery, and a radial artery graft or
aphenous vein graft was used for other coronary vessels.
In our study, post-operative complications were defined
s central nervous system disorders, cardiovascular disorders
low output syndrome, heart failure, and refractory arrhyth-
ias), respiratory failure, acute renal failure (necessitating
emodialysis), gastrointestinal disorders (gastrointestinal
ract hemorrhage, ileus, and/or hepatic dysfunction that
equired parenteral hyperalimentation), infections (sepsis, tediastinitis, and so on), and
rolonged admission to the in-
ensive care unit (ICU). The
eed for hemodialysis in patients
ith acute renal failure was de-
ermined by a nephrologist spe-
ializing in dialysis according to
he following criteria: 1) urine
utput 400 ml/day despite in-
ravenous administration of furo-
emide in addition to adequate
ost-operative fluid infusion; 2)
ersistent oliguria with an in-
rease of central venous pressure
r pulmonary capillary wedge
ressure; 3) failure to control the
erum potassium level; 4) a per-
istent rise of serum Cr despite a
esponse to intravenous fluid in-
usion; and 5) progression of
etabolic acidosis.
The levels of atrial natriuretic
eptide (ANP), plasma renin ac-
ivity (renin), angiotensin II, al-
osterone, blood urea nitrogen,
r, sodium (Na), and osmotic
ressure (Osm) were measured before surgery, on returning
o the ICU, and 1, 3, and 7 days after surgery. The
aximum value and percent increase of Cr (%Cr 
maximum Cr  pre-operative Cr]/pre-operative Cr value
100) were also determined. Urinary Na (U-Na), urinary
reatinine (U-Cr), and osmotic pressure (U-osm) were
easured before surgery, on returning to ICU, and 1, 3, and
days after surgery. Then the Ccr (Ccr  U-Cr  minute
rine output/Cr), fractional sodium excretion (FENa 
U-Na/Na]  [Cr/U-Cr]  100), free water clearance
CH20  [1-U-osm/Osm]  minute urine output/body
urface area), and renal failure index (RFI  [U-Na 
r]/U-Cr) were calculated.
tatistical analysis. Data are expressed as mean SD. For
arametric and nonparametric data, statistically significant
ifferences were determined by using the Student t test and
isher exact test, respectively. A p value of 0.05 was
onsidered to indicate statistical significance. Other data
ere analyzed by using repeated measures analysis of vari-
nce. All analyses were conducted with SPSS software
SPSS Inc., Chicago, Illinois).
esults
linical characteristics. There were no significant differ-
nces between the 2 groups with respect to pre-operative
haracteristics such the age, male/female ratio, body
urface area, underlying diseases, emergency surgery, risk
actors, and pre-operative cardiac function (ejection frac-
Abbreviations
and Acronyms
%Cr  percent increase
of creatinine
BNP  brain natriuretic
peptide
CABG  coronary artery
bypass grafting
Ccr  creatinine clearance
CH20  free water
clearance
CPB  cardiopulmonary
bypass
Cr  creatinine
FENa  fractional sodium
excretion
hANP  human atrial
natriuretic peptide
ICU  intensive care unit
OPCAB  off-pump
coronary artery bypass
RAAS  renin-angiotensin-
aldosterone system
RFI  renal failure indexion) (Table 1).
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Ef fects of hANP in Cardiac Surgery September 15, 2009:1058–64ost-operative results. Table 2 shows the number of
ypass grafts, the aortic cross-clamp time, and the CPB
ime. There were no significant differences in these variables
etween the hANP and placebo groups. The post-operative
ospital mortality rate was 1.6% (n 4) in the hANP group
nd 2.4% (n  6) in the placebo group, and there was no
ignificant difference between the 2 groups. The cause of
eath was cardiac failure in 2 patients and pneumonia in 2
atients from the hANP group, whereas it was cardiac
ailure in 3 patients, cerebral infarction in 1, pneumonia in
, and hepatic failure in 1 patient from the placebo group.
omplications occurred in 8 patients (3.2%) from the
ANP group and 20 patients (7.9%) from the placebo
roup, so significantly more patients from the latter group
eveloped complications (p 0.0208). In the hANP group,
ardiac failure, respiratory failure, and mediastinitis oc-
omparison of Patient CharacteristicsTable 1 Comparison of Patient Characteristics
hANP Group Placebo Group p Value
Patients (n) 251 253 0.437
Age (yrs) 65.6 0.6 66.3 0.6 0.255
Sex (male/female) 193/58 205/48 0.413
BSA (m2) 1.66 0.01 1.65 0.01 0.301
Diagnosis
AMI 25 16
OMI 100 93
Unstable angina 94 104
Stable angina 32 40
Emergency 75 (29.9%) 63 (24.9%) 0.210
Risk factor
DM 112 (44.6%) 110 (43.5%) 0.796
Hypertension 175 (69.7%) 179 (70.8%) 0.800
Hyperlipidemia 143 (57.0%) 151 (59.7%) 0.537
Obesity 67 (26.7%) 58 (22.9%) 0.327
Smoking 116 (46.2%) 100 (39.5%) 0.129
Ejection fraction (%) 59.5 1.4 60.9 1.1 0.410
MI  acute myocardial infarction; BSA  body surface area; DM  diabetes mellitus; hANP 
uman atrial natriuretic peptide; OMI  old myocardial infarction.
Operative and Post-Operative DataTable 2 Operative and Post-Operative Data
h
Patients (n)
Mortality
ACCT (min)
CPBT (min) 1
Bypass
Administering day (days)
Hospital stay (days)
Maximum Cr (mg/dl)
0.3 mg/dl  (pre-operative  maximum Cr)
Cr increase rate (%)
Cr 1.3 mg/dl
Cr 1.5 mg/dl
Cr 2.0 mg/dl
HemodialysisACCT  aortic cross clamp time; CPBT  cardiopulmonary bypass time; Cr urred in 4, 3, and 1 of the patients, respectively. In the
lacebo group, the complications were cardiac failure, acute
enal failure requiring hemodialysis, respiratory failure, ce-
ebral infarction, severe arrhythmia, and hepatic failure in 7,
, 3, 3, 2, and 1 of the patients, respectively. No patient
iscontinued hANP administration due to reduced blood
ressure, and no rebound was observed after discontinuation
f infusion. The hospital stay was significantly shorter in the
ANP group (p  0.0002).
The duration of hANP administration was 2.23  0.82
ays in the hANP group. In the control group, physiological
aline was infused for 2.80  1.90 days. The duration of
nfusion was significantly shorter in the hANP group (p 
.0001).
Dopamine was administered post-operatively to 145
atients (57.8%) from the hANP group and 152 patients
60.1%) from the placebo group, showing no difference.
enal function. The post-operative maximum Cr value
as 0.97 0.02 mg/dl in the hANP group and 1.14 0.03
g/dl in the placebo group, whereas %Cr was 15.7 
5.1% in the hANP group and 41.5 80.1% in the placebo
roup (Table 2).
Post-operative Cr showed an increase of 0.3 mg/dl
ompared with the pre-operative value in 40 patients from
he hANP group (15.9%) and 92 patients from the placebo
roup (36.4%), and the incidence was significantly lower in
he hANP group (p  0.0001) (Table 2).
These values were significantly higher in the placebo
roup (p  0.0001). Post-operatively, Cr increased to 1.3
g/dl or more in 20 and 61 patients from the hANP and
lacebo groups, respectively (p  0.0001), and to 1.5 mg/dl
r more in 9 and 35 patients, respectively (p  0.0001).
atients with Cr exceeding 2.0 mg/dl included 1 in the
ANP group and 8 in the placebo group, showing a
ignificant difference (p  0.0374). Four patients in the
lacebo group and none in the hANP group required
emodialysis, but the difference was not statistically signif-
roup Placebo Group p Value
1 253
6%) 6 (2.4%) 0.531
1.4 53.3 2.0 0.566
2.1 118.2 2.1 0.933
0.05 3.18 0.05 0.331
0.82 2.80 1.90 0.0001
0.4 15.1 0.7 0.0002
0.02 1.14 0.03 0.0001
92 0.0001
1.6 41.5 5.5 0.0001
61 0.0001
35 0.0001
8 0.0374
4 0.123ANP G
25
4 (1.
54.4
18.5
3.12
2.23
12.2
0.97
40
15.7
20
9
1
0creatinine; hANP  human atrial natriuretic peptide.
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September 15, 2009:1058–64 Ef fects of hANP in Cardiac Surgerycant (p  0.123) (Table 2). Ccr was significantly higher in
he hANP group from post-operative day 0 to week 1,
hereas FENa and CH20 were significantly lower in the
ANP group from post-operative day 0 to week 1 and days
to 3, respectively. RFI was significantly lower in the
ANP group from post-operative day 0 to week 1 (Table 3,
ig. 1).
NP and RAAS. ANP increased rapidly in the hANP
roup and was significantly higher than in the placebo group
ntil post-operative day 3, but there was no significant
ifference between the 2 groups at post-operative week 1
Renal Function After OperationTable 3 Renal Function After Operation
Pre-Operative Day 0
BUN (mg/dl)
hANP 15.5 0.3 15.0 0.8
Placebo 14.7 0.3 15.2 0.3
Cr (mg/dl)
hANP 0.84 0.01 0.86 0.0
Placebo 0.83 0.01 0.91 0.0
U-Cr (mg/dl)
hANP 96.2 11.5 15.3 1.4
Placebo 102.4 8.5 7.6 0.5
UO (ml/min)
hANP 0.88 0.01 5.65 0.0
Placebo 0.90 0.01 3.69 0.0
FENa (%)
hANP 1.02 0.20 8.85 0.6
Placebo 0.99 0.11 14.63 1.5
Free water clearance
hANP 0.34 0.03 0.57 0.0
Placebo 0.37 0.03 0.41 0.0
RFI
hANP 1.63 0.29 12.27 0.7
Placebo 1.12 0.08 20.64 2.2
*p  0.05, †p  0.01.
BUN  blood urea nitrogen; Ccr  creatinine clearance; Cr  creat
peptide; RFI  renal failure index; U-Cr  urine creatinine; UO  urine
0
20
40
60
80
100
120
140
hANP
Placebo
*
*
*
*
m
l/m
in
Preop   Day 0     1          3         7
Figure 1 Changes of Creatinine Clearance
Creatinine clearance was significantly higher in the human atrial
natriuretic peptide (hANP) group from post-operative day 0 to week 1. *p  0.05.oFig. 2). The levels of renin, angiotensin-II, and aldosterone
ll increased post-operatively in the placebo group, and
eached a peak at the time of the return to ICU. Afterwards,
hese parameters decreased, but did not return to the
re-operative range. On the other hand, these parameters
ere increased at the return to ICU in the hANP group, but
mproved rapidly. Angiotensin-II and aldosterone were
ignificantly lower in the hANP group throughout the
tudy. Renin was significantly lower in the hANP group,
xcluding day 1 (Figs. 2 and 3).
iscussion
eterioration of renal function after cardiac surgery is
hought to be caused by nonpulsatile perfusion, renal
ypoperfusion, stimulation of the inflammatory response,
nhancement of RAAS activity, and renal tubular necrosis
19,20). We previously reported that continuous infusion of
ow-dose hANP from the start of CPB suppresses retention
f water in a third space, suppresses RAAS activity, and has
potent diuretic effect, thus compensating for the adverse
ffects of cardiopulmonary bypass (16). The present ran-
omized controlled study was performed to investigate the
ffect of hANP on post-operative renal function. The results
emonstrated that post-operative transient deterioration of
enal function associated with CABG can be prevented by
ontinuous infusion of low-dose hANP during and after
urgery. In the patients receiving physiological saline infu-
ion (placebo group), Ccr showed a decline to around
Day 1 Day 3 Week 1
18.5 0.4 22.6 0.5* 22.1 0.5†
18.9 0.5 24.7 0.7 25.0 0.8
0.93 0.03† 0.79 0.01† 0.80 0.01†
1.06 0.03 1.00 0.03 1.00 0.03
77.1 2.8† 69.8 2.2† 101.3 2.9†
47.9 2.3 58.2 2.4 86.4 3.0
1.56 0.02† 1.41 0.02† 0.82 0.01*
1.22 0.03 1.13 0.02 0.78 0.01
1.31 0.14† 1.18 0.07† 0.55 0.03†
2.41 0.27 1.85 0.16 0.78 0.07
0.92 0.05* 0.96 0.04† 050 0.03
0.69 0.07 0.67 0.03 0.45 0.02
1.80 0.18† 1.64 1.00† 0.76 0.04†
3.35 0.36 2.54 0.22 1.09 0.10
ENa  fractional sodium excretion; hANP  human atrial natriuretic
t.1*
2
†
6†
6
6†
8
7*
5
8†
6ne-third of the pre-operative level when they returned to
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Ef fects of hANP in Cardiac Surgery September 15, 2009:1058–64CU after surgery, and it was still below the pre-operative
alue 1 week later. In contrast, the pre-operative Ccr could
e maintained in the patients receiving hANP infusion, and
one of them required hemodialysis post-operatively. Pa-
ients requiring post-operative hemodialysis showed no
ignificant difference between the hANP and placebo
roups, but patients with Cr exceeding 2.0 g/dl were
ignificantly more common in the placebo group. In this
tudy, it was important that post-operative hemodialysis was
ot required by any patients in the hANP group. When the
ame study is performed on patients with pre-operative
ecreases in renal function, it is assumed to be highly
ossible that the hANP administration would show a
ecrease in the number of patients placed on hemodialysis
ost-operatively. At present, the study on patients with
re-operative decreases in renal function is now in progress,
nd it is hoped that the efficacy of hANP administration will
e shown. Analysis of FENa indicated a natriuretic effect of
ANP, whereas the data on CH20 supported a preventive
Figure 2 Changes of ANP and Plasma Renin Activity
Atrial natriuretic peptide (ANP) increased rapidly in the human atrial natriuretic pep
post-operative day 3, but there was no significant difference between the 2 groups at
*p  0.05.
Figure 3 Changes of Angiotensin-II and Aldosterone
The levels of angiotensin-II and aldosterone increased post-operatively in the place
to intensive care unit. Angiotensin-II and aldosterone were significantly lower in theffect of hANP infusion against impairment of urine con-
entration. Because of its RAAS-suppressing effect, to-
ether with the above-mentioned activities, low-dose infu-
ion of hANP seems to quickly improve CPB-related
lomerular dysfunction, humoral imbalances, and liquidity
actor impairment, and thus maintains a more physiological
tate.
Brown et al. (21) studied 1,391 patients with normal
enal function who underwent cardiac surgery, and reported
hat the mortality was significantly higher in patients with a
Cr of 50% or more than in those with a value of 25% or
ess, suggesting that it is necessary to preserve renal function
erioperatively. In the present study, %Cr was significantly
ower in the hANP group than in the placebo group, and
ccordingly, we conclude that intraoperative administration
f hANP prevented perioperative renal dysfunction.
Various effects of hANP on the kidneys have been
eported, and it is considered to act directly on the renal
ubules (exhibiting a diuretic effect) and thereby prevent
ANP) group and was significantly higher than in the placebo group until
perative week 1. Renin was significantly lower in the hANP group excluding day 1.
up, and reached a peak at the time of the return
n atrial natriuretic peptide (hANP) group throughout the study. *p  0.05.tide (h
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September 15, 2009:1058–64 Ef fects of hANP in Cardiac Surgeryeterioration of the electrolyte balance, increased urinary
odium excretion, and renal parenchymal damage caused by
dministration of high-dose diuretics (22). However, few
tudies have assessed the effects of hANP in patients having
ardiac surgery, including efficacy for preventing acute renal
ailure. Valsson et al. (23) administered hANP for 30 min to
atients with acute renal failure and cardiac failure, and
ound that the urine output, glomerular filtration rate, and
enal blood flow increased by 62%, 43%, and 38%, respec-
ively, whereas renal vascular resistance decreased by 30%.
hey also performed a larger study and reported that the
eed for hemodialysis was decreased by hANP, and hence
ialysis-free survival was improved (24). The only studies to
ssess prevention of acute renal failure have been our
revious study (16–18) and a study by Hayashida et al. (25),
oth of which were small in scale. Hayashida reported that
he hANP group showed significantly higher urine output
han the placebo group, and had better hemodynamics and
ater balance. The present large-scale study demonstrated
hat intraoperative infusion of hANP could prevent post-
perative deterioration of renal function. It is extremely
ifficult to predict which patients with normal renal func-
ion pre-operatively will develop acute renal failure after
ardiac surgery, but the present study showed that hANP
an prevent the onset of acute post-operative renal failure.
ecause hANP was developed in Japan, it is only available
n our country so far. Brain natriuretic peptide (BNP)
nesiritide) has not been approved in Japan, but is available
n Western countries. An interesting study on administra-
ion of BNP during cardiac surgery was performed in the
.S. When BNP was administered to patients with pre-
perative renal dysfunction or left ventricular dysfunction,
ost-operative plasma levels of cystatin, aldosterone, and
r, as well as the estimated Ccr, were better in the BNP
roup (26,27). A comparison of clinical efficacy between
ANP and BNP has never been reported. However, it is
nown that hANP has a shorter elimination half-life than
NP and therefore may be safer to use. Both hANP and
NP are reported to be very effective for the improvement
f renal dysfunction and cardiac dysfunction, and perioper-
tive administration of either peptide can reduce the inci-
ence of post-operative complications and contribute to
afer cardiac surgery.
A previous large-scale multicenter study of hANP infu-
ion after reperfusion therapy for acute myocardial infarc-
ion showed that the hANP group had a significant decrease
n infarct size, better cardiac function, and significantly
ower rates of cardiac death and cardiac failure compared
ith the placebo group (28). The present study is to our
nowledge the first assessment of hANP in more than 500
atients undergoing cardiac surgery, and it demonstrates
hat continuous infusion of low-dose hANP from the start
f CPB improves renal function post-operatively, maintains
more physiological state, and compensates for the adverse
ffects of CPB. Adding hANP treatment to the periopera-
ive management of cardiac surgery can prevent deteriora-
1ion of renal function and allows surgery to be performed
ore safely. We found that hANP was effective at a low
ose of 0.02 g/kg/min, and no clinically significant hypo-
ension or rebound was detected at this dose.
The present study demonstrates the efficacy of perioper-
tive hANP infusion for protection of renal function. It
eems likely that hANP administration will be more effec-
ive in patients with pre-operative renal dysfunction, cardiac
ysfunction, or diabetes mellitus. Currently, we are con-
ucting a trial in such patients to test this hypothesis.
onclusions
he present study evaluated the effect on renal function of
ontinuous infusion of low-dose hANP from start of CPB.
e demonstrated that hANP suppresses RAAS activity,
as a potent natriuretic action, prevents post-operative renal
ysfunction, and compensates for the adverse effects of
PB. Thus, hANP is a promising agent for the periopera-
ive management of patients undergoing cardiac surgery
ith CPB.
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